Diabetic retinopathy has become one of the four most common causes of blindness in the United States.1 Although photocoagulation has been employed in its treatment for more than ten years, its true value remains controversial. In spite of the need for objective, definitive evidence, an adequately controlled study of photocoagulation in the treatment of proliferative diabetic retinopathy has not been performed. This is not surprising, considering the complexity and expense of largescale clinical trials in chronic disease. However, as Inglefinger2 has aptly stated, "When serious diseases are treated by serious methods... then ethical as well as scientific considerations require that medicine depend on the most reliable and the best controlled data available—the kind of data that is sought by randomized clinical study."
In keeping with this admonition, a randomized clinical trial of photocoagulation in the treatment of proliferative diabetic retinopathy has been designed and launched. This study
Aiello LM, Berrocal J, Davis MD, et al. The Diabetic Retinopathy Study. Arch Ophthalmol. 1973;90(5):347–348. doi:10.1001/archopht.1973.01000050349001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: